Copyright
©The Author(s) 2020.
World J Gastroenterol. Sep 28, 2020; 26(36): 5420-5436
Published online Sep 28, 2020. doi: 10.3748/wjg.v26.i36.5420
Published online Sep 28, 2020. doi: 10.3748/wjg.v26.i36.5420
Figure 2 Granulocyte-macrophage colony-stimulating factor normalized cytokine profiles and regulated Toll-like receptor expression.
A: Cytokine levels in serum; B and C: Cytokine gene expression in the liver and colon. Data are presented as the means ± SE and analyzed via one-way ANOVA with post hoc Tukey’s test. n = 11-13 mice per group. aP < 0.05, bP < 0.01, and eP < 0.001 hepatocellular carcinoma (HCC) vs control; cP < 0.05, dP < 0.01, and fP < 0.001 HCC + GM-CSF vs HCC. IL-1β: Interleukin-1β; TGFβ: Transforming growth factor β; HCC: Hepatocellular carcinoma; GM-CSF: Granulocyte-macrophage colony-stimulating factor.
- Citation: Wu YN, Zhang L, Chen T, Li X, He LH, Liu GX. Granulocyte-macrophage colony-stimulating factor protects mice against hepatocellular carcinoma by ameliorating intestinal dysbiosis and attenuating inflammation. World J Gastroenterol 2020; 26(36): 5420-5436
- URL: https://www.wjgnet.com/1007-9327/full/v26/i36/5420.htm
- DOI: https://dx.doi.org/10.3748/wjg.v26.i36.5420